##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|||||||2021|2020|
|---|---|---|---|---|---|---|---|
|||||Unrestricted|Restricted|Total|Total|
|||||fund|funds|funds|funds|
||||Notes||F|||
|INCOME AND ENDOWMENTS||FROM||||||
|Donations
and legacies|||3|1,726,274||1,726,274|1,053,057|
|Other trading
activities|||4|324,408||324,408|1,027,062|
|Investment
income|||5|104,967||104,967|114,321|
|Other income|||6|59,362||59,362|20,701|
|Total||||2,215,011||2,215,011|2,215,141|
|EXPENDITURE ON||||||||
|Raising funds||||583,814||583,814|862,505|
|Charitable
activities||||||||
|Research projects||||883,695|8,397|892092|2 544 440|
|Total||||1,467,509|8,397|1,475,906|3,406,945|
|Net gains/(losses)
on|investments|||756,570||756.570|~155,705)|
|NET INCOME/(EXPENDITURE)||||1,504,072|(8,397)|1,495,675|(1,347,509)|
|RECONCILIATION
OF FUNDS||||||||
|Total funds brought|forward|||3,455,034|365,408|3,820,442|5,167,951|
|TOTAL FUNDS CARRIED FORWARD||||4,959,106|357,011|5,316,117|3,820,442|
##
##
||||||||2021||
|---|---|---|---|---|---|---|---|---|
|||||Urfrestricted|Restrfrsted||Total|Tefal|
|||||fUnd|iUnci 5||IUIICo|fUI
'.ras|
|||||C|k||6||
|FlXED ASSETS
li rtai19fbtLa assetS
Tal"I&I".bfe issets
ff1VLasf irrerfte|||trrf
17
I or|«,889
2='i,!82
*.301..:65|||4,889
25,782
!,80i,865|9 !8eJ
29 !35-1
3.I88, 05|
|||||4,832,536|||4,8 r2,53!&|",' 'L'I.-, U18|
|CURRENT ASSETS
Qebtors
Cash ai barite arid
i'.1 "Brief|||:9|7 '.9,258
2,807,760|365a408||749
r58
3,1 s3.168|508, 774
3 f24,957|
|||||3557,018|365.-'08||3,922.426: .533731||
|CREDITORS
Ai'IIC'irrtftS
ialllflti 6'I . VSil)iln «iii||)refdr|20|i;620428t|i8 3$71||i'628,825;|f396,34"i;|
|NET CUPPENT ASSETS||||;?,936,590|357,0t|1|3, .9i,601|3il37,390|
|TOT~P
ASSETS|LESSCURRENT UABiLITfES|||i',769,126|35,0|1|8.t26it37|7,184,038|
|PRGVfSIONS FOR LfABILfTfES|||22|!2,8 f0,020)|||(2,810,020 i|(3,34':.598(|
|||||l,959,":0I6|37ti"1||~ !6i 7|3 II2s0,442|
|Unre
Iri-ted!!Inde|||||||4,95Cs,106|~,»5-,0s4|
|Lostnctedi
',Uirds|||||||||
|TOTALFUNDS|||||||5.316,117|"-',820,442|
##
##
||||2021|2020|
|---|---|---|---|---|
|||Notes|E|F|
|Cash flows from operating|activities||||
|Cash generated
from operations|||104,805|238,121|
|Interest paid||||5|
|Net cash provided
by operating
activities|||104,805|238,126|
|Cash flows from investing|activities||||
|Purchase of intangible
fixed assets
Purchase oftangible
fixed assets|||(4,670)|(11,935)
(14,340)|
|Purchase offixed asset investments
Sale of intangible
fixed assets
Sale oftangible
fixed assets|||(1,064,361)|(1,263,532)
(30,530)
38,530|
|Sale offixed asset investments|||1,007,471|1,169,718|
|Interest received|||18,064|19,363|
|Dividends
received|||86,902|94,958|
|Net cash (used in)/provided|by investing|activities|43,406|2,232|
|Change
in cash and cash|equivalents|in|||
|the reporting
period|||148,211|240,358|
|Cash and cash equivalents|at the||||
|beginning
ofthe reporting|period||3,024,957|2,784,599|
|Cash and cash equivalents|at the end|of|||
|the reporting
period|||3,173,168|3,024,957|
##
##
|ACTIVITIES|||||||
|---|---|---|---|---|---|---|
||||||2021|2020|
||||||F|f|
|Net income/(expenditure)||for the reporting|period (as per the||||
|Statement of Financial Activities)
Adjustments
for:|||||1,495,675|(1,347,509)|
|Depreciation
charges|||||12,242|15,044|
|(Gain)/losses
on investments|||||(786,038)|202,311|
|Loss on disposal of|fixed assets|||||30,546|
|Interest received|||||(18,064)|(19,363)|
|Interest paid
Dividends
received|||||(86,902)|(5)
(94,958)|
|Discounting
of provisions|||||29,468|(18,720)|
|Dilapidations
provision||||||150,996|
|Decrease
in stocks||||||1,120|
|(Increase)/decrease|in debtors||||(240,484)|487,321|
|(Decrease)/increase|in creditors||||~3O1,092|831,338|
|Net cash provided|by operations||||104,805|238,121|
|ANALYSIS OF CHANGES||IN NET FUNDS|||||
|||||At 1/4/20
F|Cash flow
f|At 31/3/21
F|
|Net cash|||||||
|Cash at bank and in|hand|||3,024,957|148,211|3,173,168|
|||||3,024,957|148,211|3,173,168|
|Total||||3,024,957|148,211|3,173,168|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|OTHER INCOME|||||||||
|---|---|---|---|---|---|---|---|---|
||||||||2021|2020|
|||||||||F|
|Discounting
of provisions|||||||(29,468)|18,720|
|Insurance
claim|||||||85,830||
|Miscellaneous
income|||||||3,000|1,981|
||||||||59,362|20,701|
|RAISING FUNDS|||||||||
|Raising donations|and||legacies||||||
||||||||2021|2020f|
|Fundraising
staff costs|||||||211,940|192,040|
|Gift aid and legacy|expenses||||||3,513|6,710|
|Events and general|fundraising|||expenditure|||11,002|68,819|
|Advertising
and publicity|||||||928|9,836|
|Other fundraising
expenses|||||||6,180|24,638|
|Depreciation|||||||412|476|
||||||||233,975|302,519|
|Other trading activities|||||||||
||||||||2021|2020|
|Retail staff costs|||||||151,434|169,299|
|Retail purchases|||||||920|7,038|
|Retail and warehouse||premises||costs|||131,348|143,109|
|Other retail costs|||||||24,301|44,849|
|Merchandise
purchases|||including||Christmas|cards|3,985|4,814|
|Dilapidations||||||||150,996|
|Depreciation|||||||7,255|9,718|
|Loss on sale ofassets||||||||16|
||||||||319,243|529,839|
##
|RAISING FUNDS - continued|RAISING FUNDS - continued|RAISING FUNDS - continued|RAISING FUNDS - continued|RAISING FUNDS - continued|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|Investment|management|||costs|||||||
||||||||||2021|2020|
|||||||||||F|
|Investment|management|||costs|||||30,596|30,147|
|Aggregate|amounts||||||||583,814|862,505|
|CHARITABLE ACTIVITIES COSTS|||||||||||
||||||||Grant||||
||||||||funding|of|||
|||||||Direct|activities||Support||
|||||||Costs (see|(see note||costs (see||
|||||||note 9)|10)||note 11)|Totals|
|||||||F|F|||F|
|Research|projects|||||126,302|456,287||309,503|892,092|
|DIRECT COSTS OF CHARITABLE ACTIVITIES|||||||||||
||||||||||2021|2020|
||||||||||F|F|
|Staff costs|||||||||96,568|86,886|
|Direct cancer research|||expenditure||||||20,740|(3,811)|
|Science communication||||costs|||||8,719|320|
|Depreciation|||||||||275|317|
||||||||||126,302|83,712|
|GRANTS|PAYABLE||||||||||
||||||||||2021|2020|
||||||||||F|F|
|Research|projects||||||||456,287|2,117,505|
|The total grants
paid to|||institutions||during the year|was as follows:|||||
||||||||||2021|2020|
|||||||||||F|
|Velindre
NHS Trust|||||||||147,731|79,341|
|Cardiff University|||||||||266,132|1,571,045|
|Bangor University
Other adjustments||on project closures|||||||47,000
~4,576)|481,322
~14,203)|
||||||||||456,287|2,117,505|
##
##
##
##
##
|STAFF COS|TS|||||||
|---|---|---|---|---|---|---|---|
|||||||2021|2020|
|||||||f.|f|
|Wages and salaries||||||575,617|553,227|
|Redundancy|costs|||||23,855||
|Social security costs||||||52,819|46,787|
|Pension||||||50,760|46,141|
|||||||703,051|646,155|
|The average|monthly|number ofemployees||during the year was as follows:||||
|||||||2021|2020|
|Fundraising||||||6|6|
|Retail||||||7|7|
|Administration/|Governance|||||6|7|
|||||||19|20|
|The number|ofemployees||whose emoluments|amounted|toa rate ofover F60,000|during the year were as follow||
|||||||2021|2020|
|||||||No.|No.|
|F60,001 - F70,000||||||1||
|Pension contributions||||||9,100||
##
##
||||Unrestricted|Restricted|Total|
|---|---|---|---|---|---|
||||fund|funds|funds|
||||F|||
|INCOME AND ENDOWMENTS||FROM||||
|Donations
and legacies|||1,053,057||1,053,057|
|Other trading
activities|||981,074|45,988|1,027,062|
|Investment
income|||114,321||114,321|
|Other income|||20,701||20,701|
|Total|||2,169,153|45,988|2,215,141|
|EXPENDITURE ON||||||
|Raising funds|||862,505||862,505|
|Charitable
activities||||||
|Research projects|||2,544,440||2,544,440|
|Total|||3,406,945||3,406,945|
|Net gains/(losses)
on|investments||~155,705)||~155,705)|
|NET INCOME/(EXPENDITURE)|||(1,393,497)|45,988|(1,347,509)|
|RECONCILIATION
OF FUNDS||||||
|Total funds brought|forward||4,848,531|319,420|5,167,951|
|TOTAL FUNDS CARRIED FORWARD|||3,455,034|365,408|3,820,442|
##
##
##
||||||||2021|2020|
|---|---|---|---|---|---|---|---|---|
|Financial|assets||||||F|F|
|Financial|assets that are debt instruments|||measured|at amortised|cost|3,898,333|3,502,762|
|Financial|assets measured||at fair value||||4,689,108|3,988,405|
||||||||2021|2020|
|Financial|liabilities||||||||
|Financial|liabilities|measured|at amortised|cost|||475,288|396,341|
|Financial|liabilities|measured|at fair value||||2,810,020|3,343,596|
##
##
|INTANGIBLE FIXEDASSETS||
|---|---|
||Computer|
||software|
||P|
|COST||
|At 1 April 2020 and 31 March 2021|14,922|
|AMORTISATION||
|At 1 April 2020|5,733|
|Charge for year|4,300|
|At 31 March 2021|10,033|
|NET BOOK VALUE||
|At 31 March 2021|4,889|
|At 31 March 2020|9,189|
##
##
|TANGIBLE FIXEDASSETS|||||
|---|---|---|---|---|
||Leasehold||||
||property|Fixtures|Motor||
||improvements|8 Equipment|vehicles|Totals|
|COST|||||
|At 1 April 2020|103,101|37,897|20,216|161,214|
|Additions|4,670|||4,670|
|At 31 March 2021|107,771|37,897|20,216|165,884|
|DEPRECIATION|||||
|At 1 April 2020|96,971|18,342|16,847|132,160|
|Charge for year|3,027|3,611|1,304|7,942|
|At 31 March 2021|99,998|21,953|18,151|140,102|
|NET BOOK VALUE|||||
|At 31 March 2021|7,773|15,944|2,065|25,782|
|At 31 March 2020|6,130|19,555|3,369|29,054|
|18.|FIXEDASSET INVESTMENTS|FIXEDASSET INVESTMENTS|FIXEDASSET INVESTMENTS|FIXEDASSET INVESTMENTS||||
|---|---|---|---|---|---|---|---|
||||||||Investments|
||MARKET|VALUE||||||
||At 1 April|2020|||||3,988,405|
||Additions||||||1,064,361|
||Disposals||||||(1,007,471)|
||Revaluations||||||756,570|
||At 31 March 2021||||||4,801,865|
||NET BOOK VALUE|||||||
||At 31 March 2021||||||4,801,865|
||At 31 March 2020||||||3,988,405|
|||||||2021|2020|
||||||||F|
||Historical|cost of investments||||3,586,443|3,588,929|
||Analysis|ofinvestments||between funds:||||
|||||||2021|2020|
||Listed investments|||||4,780,526|3,988,405|
||UK cash|held as part of portfolio||||21,339||
|||||||4,801,865|3,988,405|
||Cost or valuation||at 31 March 2021 is represented||by:|||
||||||||Investments|
||||||||f|
||Valuation|in 2020|||||458,852|
||Valuation|in 2021|||||756,570|
||Cost||||||3,586,443|
||||||||4,801,865|
|19.|DEBTORS:AMOUNTS|||FALLING DUE WITHIN|ONE YEAR|||
|||||||2021|2020|
|||||||F||
||Other debtors|||||71,540||
||Legacies
VAT|due||||569,725|477,805
5,793|
||Prepayments
and||accrued income|||107,993|25,176|
|||||||749,258|508,774|
##
##
##
|CREDITORS:|AMOUN|TS|FALLING DUE WITHIN ONE Y|EAR||
|---|---|---|---|---|---|
|||||2021|2020|
||||||E|
|VAT payable||||5,918||
|Social security|and other||taxes|13,223||
|Project funding|payments||due|279,081|351,947|
|Other creditors||||150,346|32,486|
|Accruals and deferred||income||180,257|11,908|
|||||628,825|396,341|
##
##
|Minimum
lease payments
under non-cancellable
operating|leases fall due as follows:||
|---|---|---|
||2021|2020|
|||Z|
|Within one year|59,000|62,115|
|Between one and five years|26,625|84,625|
||85,625|146,740|
##
##
||||2021|2020|
|---|---|---|---|---|
|Project grant commitments|||2,659,024|3,192,600|
|Dilapidations
provision|||150,996|150,996|
||||2,810,020|3,343,596|
|||||Project grant|
|||||commitments|
|||||F|
|Balance at 1 April|2020|||3,192,600|
|New project grant|commitments|||460,866|
|Grants payable
in|the year|||(1,019,332)|
|Grant underspend|written|back||(4,578)|
|Discounting
ofprovisions||||29,468|
|Balance at 31 March 2021||||2,659,024|
##
|23.|MOVEMENT|MOVEMENT|IN FUNDS|IN FUNDS|||||||
|---|---|---|---|---|---|---|---|---|---|---|
||||||||||Net||
||||||||||movement|At|
|||||||||At 1/4/20|in funds|31/3/21|
||||||||||F||
||Unrestricted||funds||||||||
||General
fund|||||||3,455,034|1,504,072|4,959,106|
||Restricted|funds|||||||||
||Brain Tumour||Scholarship|||||150,000||150,000|
||Bowel Cancer||Research||Fund|||61,920||61,920|
||Tom Walker|Fund -||Acute Myeloid|||||||
||Leukaemia|||||||145,988|(8,397)|137,591|
||Millennium|Stadium||Charitable||Trust||7,500||7,500|
|||||||||365,408|8,397|357,011|
||TOTAL FUNDS|||||||3,820,442|1,495,675|5,316,117|
||Net movement||in funds,||included||in the above are as follows:||||
||||||||Incoming|Resources|Gains and|Movement|
||||||||resources
f|expended
F|losses|in funds|
||Unrestricted||funds||||||||
||General
fund||||||2,215,011|(1,467,509)|756,570|1,504,072|
||Restricted|funds|||||||||
||Tom Walker|Fund -||Acute Myeloid|||||||
||Leukaemia|||||||(8,397)||(8,397)|
||TOTAL FUNDS||||||2,215,011|~1,475,906)|756,57D|1,495,675|
##
|Comparativ|es|for|move|ment|in funds||||
|---|---|---|---|---|---|---|---|---|
||||||||Net||
||||||||movement|At|
|||||||At 1/4/19|in funds|31/3/20|
|||||||F|F||
|Unrestricted||funds|||||||
|General
fund||||||4,848,531|(1,393,497)|3,455,034|
|Restricted|funds||||||||
|Brain Tumour||Scholarship||||150,000||150,000|
|Bowel Cancer Research||||Fund||61,920||61,920|
|Tom Walker|Fund -||Acute|Myeloid|||||
|Leukaemia||||||100,000|45,988|145,988|
|Millennium|Stadium||Charitable||Trust|7,500||7,500|
|||||||319,420|45,988|365,408|
|TOTAL FUNDS||||||5,167,951|~1,347,509)|3,820,442|
##
##
##
##
##
##
##